Herman Meinders and the Meinders Foundation have combined for an $8 million donation to the Oklahoma Medical Research Foundation. The gift aims to transform neurodegenerative disease research in Oklahoma.
OMRF will add a new floor to its research tower that will serve as the hub for the Meinders Center for Neurodegenerative Research, the state’s first dedicated center to study brain diseases, including Parkinson’s and Alzheimer’s.
Meinders, an Oklahoma City businessman and philanthropist, contributed $2 million toward this gift before he died in March. The Meinders Foundation then increased the gift by an additional $6 million.
“This generous donation will help us build upon the groundbreaking discoveries our scientists have already made involving neurodegenerative diseases,” said OMRF President Andrew Weyrich, Ph.D. “Our ultimate goal is to improve diagnostics and treatment options for the millions of Americans who live with one of these debilitating diseases.”
At OMRF, 10 scientists lead labs that study various aspects of neurodegenerative diseases. The combined gift by Herman Meinders and the Meinders Foundation will integrate the work of these labs, leading to a more comprehensive understanding of the causes behind brain disorders, including the environmental and genetic factors that increase the risk of developing one.
Meinders and his wife, LaDonna, were passionate supporters of causes that included research and treatment of neurodegenerative diseases. Their gifts established the Meinders NeuroScience Institute and the Meinders Center for Movement Disorders at Oklahoma City’s Mercy Hospital. Both centers provide advanced treatment for Parkinson’s disease, which Herman Meinders lived with over his final 10 years.
The couple also were longtime supporters of OMRF, and their foundation became aware of OMRF’s focus on neurodegenerative diseases shortly before Herman’s death.
OMRF scientist Mike Beckstead, Ph.D., had recently been awarded a National Institutes of Health grant to create novel research model for Parkinson’s research. Mo Grotjohn, treasurer and trustee for the Meinders Foundation, read a resulting newspaper article about the grant a few weeks before Herman’s death.
“As I learned about Dr. Beckstead’s research, I became convinced this was an endeavor worth pursuing, so I contacted OMRF Board Chair Len Cason and shared the information with members of the Meinders family,” Grotjohn said.
In Parkinson’s, nerve cells produce less dopamine, resulting in a loss of muscle control, balance and movement. It is second only behind Alzheimer’s as the most common neurodegenerative disease, affecting an estimated 1 million people in the U.S. and 10 million worldwide.
In addition to studying Parkinson’s and Alzheimer’s, OMRF scientists have made major breakthroughs for people living with other brain diseases.
For example, research at OMRF led to the only treatment approved by the Food and Drug Administration for neuromyelitis optica, which robs people of movement, balance and sight. OMRF scientists also pioneered an investigational drug for glioblastoma, a deadly form of brain cancer.
“With this gift from Herman Meinders and the Meinders Foundation, we hope to make similarly meaningful headway toward improved treatments for Parkinson’s and Alzheimer’s,” Weyrich said. “Doing so would honor the memory of Mr. Meinders.”
